Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Alkermes’ alixorexton narcolepsy type 2 study highlights the potential of orexin receptor therapy to improve daytime wakefulness as Phase 3 testing examines dosing, safety and broader clinical benefit.
Pharma & Biotech

Alkermes’ alixorexton improves narcolepsy type 2 symptoms as Phase 3 risk comes into focus

Discover how Alkermes’ alixorexton could reshape narcolepsy type 2 treatment as Phase 3 tests its efficacy, dosing and long-term safety.

Read More
Representative image: A neurological researcher reviews advanced brain scans as uniQure prepares a potential FDA filing for AMT-130, its experimental gene therapy designed to slow Huntington’s disease progression.
Pharma & Biotech

FDA accepts uniQure’s AMT-130 filing strategy after months of regulatory uncertainty

Explore why the FDA reopened uniQure’s AMT-130 approval path and what evidence, surgical and confirmatory trial risks remain before review.

Read More
Representative image: Corcept Therapeutics has resubmitted the relacorilant New Drug Application for Cushing’s syndrome, reopening FDA scrutiny of efficacy, trial design and liver safety evidence.
Pharma & Biotech

Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains

Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.

Read More
Representative image: Researchers use artificial intelligence and machine learning to design tumour-targeting multispecific antibodies, reflecting the LabGenius Therapeutics and LG Chem collaboration aimed at improving precision and safety in solid tumour treatment.
Pharma & Biotech

LabGenius-LG Chem deal tests whether AI can improve solid-tumour treatment precision

Discover how LabGenius and LG Chem aim to use AI-designed multispecific antibodies to reduce solid-tumour toxicity and reshape oncology R&D.

Read More
Pharma & Biotech

Zydus Lifesciences’ Assertio merger signals a bigger push beyond generics into U.S. oncology

Find out how Zydus Lifesciences’ Assertio merger could reshape its U.S. oncology supportive-care strategy and Rolvedon growth.

Read More
Pharma & Biotech

Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?

Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.

Read More
Representative image: Biocytogen’s AAALAC accreditation highlights the growing importance of preclinical research quality, animal care standards and antibody drug discovery credibility in translational medicine.
Pharma & Biotech

Why Biocytogen’s Boston accreditation matters for antibody discovery partners

Find out how Biocytogen’s AAALAC accreditation could strengthen preclinical research credibility and partner confidence.

Read More
Pharma & Biotech

Why Ascendis Pharma’s 182-week YORVIPATH data could matter for rare endocrine care

Find out how Ascendis Pharma’s YORVIPATH data could reshape hypoparathyroidism care and investor expectations.

Read More
Pharma & Biotech

Why EMA orphan status gives Zai Lab’s zoci more than a regulatory credibility boost

Find out how Zai Lab’s zocilurtatug pelitecan could reshape DLL3-targeted cancer therapy as development risks remain.

Read More
Pharma & Biotech

Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?

Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.

Read More